| Summary: |
The REDDSTAR Project has the potential to significantly impact the management and treatment of diabetes, with relevance for clinicians, researchers in diabetes and regenerative medicine, drug/pharmaceutical companies and ultimately for the general public. The project aims to improve the treatments available for diabetic patients, to enhance their health and quality of life. Ultimately it is hoped that such improvements would lead to a reduction in public health costs associated with diabetes and related complications.
The project includes a number of innovative elements, including those set out below:
Control of Blood Glucose and Treatment of Complications
There is currently no available treatment that will improve control of blood glucose and simultaneously address underlying diabetic complications. The REDDSTAR Project is novel in its reach across the control of blood glucose and the improvement of a range of serious tissue complications.
Collaboration
Up to now individual diabetic complications have tended to be focused on in isolation, so potential synergies and knowledge sharing between teams has not realized its full potential. The broad scope of the REDDSTAR project requires unprecedented collaboration between specialists in diverse areas. Common standard operating procedures, data collection and storage mechanisms will enable valuable comparisons and correlations between samples and results. The Project also aims to establish and maintain a virtual research community to encourage a multi-disciplinary approach to diabetes/complications research into the future.
SSC and Nanosorter®
The REDDSTAR project will involve the use of an antibody (ORB1) identified by REDDSTAR partners which isolates ORB1 + SSC, enabling testing of pure ORB1+ and ORB1- SSC and mixed PA-SSC from different species for the first time.
As part of the project, REDDSTAR partners Owl Biomedical Inc. are developing the world's first bench-top GMP-compliant [1]Nanos  |
Summary
The REDDSTAR Project has the potential to significantly impact the management and treatment of diabetes, with relevance for clinicians, researchers in diabetes and regenerative medicine, drug/pharmaceutical companies and ultimately for the general public. The project aims to improve the treatments available for diabetic patients, to enhance their health and quality of life. Ultimately it is hoped that such improvements would lead to a reduction in public health costs associated with diabetes and related complications.
The project includes a number of innovative elements, including those set out below:
Control of Blood Glucose and Treatment of Complications
There is currently no available treatment that will improve control of blood glucose and simultaneously address underlying diabetic complications. The REDDSTAR Project is novel in its reach across the control of blood glucose and the improvement of a range of serious tissue complications.
Collaboration
Up to now individual diabetic complications have tended to be focused on in isolation, so potential synergies and knowledge sharing between teams has not realized its full potential. The broad scope of the REDDSTAR project requires unprecedented collaboration between specialists in diverse areas. Common standard operating procedures, data collection and storage mechanisms will enable valuable comparisons and correlations between samples and results. The Project also aims to establish and maintain a virtual research community to encourage a multi-disciplinary approach to diabetes/complications research into the future.
SSC and Nanosorter®
The REDDSTAR project will involve the use of an antibody (ORB1) identified by REDDSTAR partners which isolates ORB1 + SSC, enabling testing of pure ORB1+ and ORB1- SSC and mixed PA-SSC from different species for the first time.
As part of the project, REDDSTAR partners Owl Biomedical Inc. are developing the world's first bench-top GMP-compliant [1]Nanosorter® in order to produce ORB1+ and ORB1- SSC for human clinical safety trials that will meet future therapeutic regulatory requirements. The Nanosorter® will be used to manufacture cGMP-compliant clinical doses of SSC at LUMC which will be administered in the REDDSTAR Phase 1b clinical study at Steno.
Our Results
Our results will generate new knowledge in respect of diabetes and related complications, but the results will also have practical application so that this new knowledge can be applied in a clinical setting. While the results will be obtained in the context of research into diabetes, they will have application for similar conditions which arise from different causes. |